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cyclopropanecarboxamide (cyclopropylfentanyl)
In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In September 2017, the EMCDDA and Europol examined 
the available information on the new psychoactive 
substance N-phenyl-N-[1-(2-phenylethyl)piperidin-
4-yl]cyclopropanecarboxamide, commonly known as 
cyclopropylfentanyl, through a joint assessment based upon 
the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on cyclopropylfentanyl satisfied criteria 4 and 6. The 
two agencies therefore concluded that sufficient information 
had been accumulated to merit the production of a Joint 
Report on cyclopropylfentanyl as stipulated by Article 5.1 of 
the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 12 
October 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on cyclopropylfentanyl, in order 
to prepare the Joint Report. The information was collected 
mainly through the Reitox national focal points in the Member 
States, Turkey, Norway, as well as the Europol national units. In 
addition, the EMA collected information through the national 
competent authorities responsible for human and veterinary 
medicinal products in the Member States as well as in Norway, 
Iceland, and Liechtenstein. The EMA also provided information 
as relevant to the centralised procedure for authorising 
medicinal products. The information collection process was 
largely concluded by 23 November 2017.
(1) OJ L 127, 20.5.2005, p. 32. 
Information collected by Europol
Europol asked the Europol national units to provide 
information on:
 ¡ the level of production of cyclopropylfentanyl in their 
country;
 ¡ the level of distribution of cyclopropylfentanyl in their 
country;
 ¡ the level of trafficking of cyclopropylfentanyl in their 
country, both for internal, transit, or export purposes;
 ¡ the number of seizures of cyclopropylfentanyl in their 
country, the total amount of the seizures, country of origin, 
and details on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, 
in the production, distribution, and trafficking of 
cyclopropylfentanyl in their country; and,
 ¡ any known aspect of violence and/or money 
laundering relating to the production and trafficking of 
cyclopropylfentanyl.
Europol received responses from 20 Member States (2), the 
Republic of Serbia, and Canada.
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the 
Member States, Norway, Iceland, and Liechtenstein provide 
information on whether:
 ¡ the new psychoactive substance cyclopropylfentanyl has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance cyclopropylfentanyl is the 
subject of an application for a marketing authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
to the new psychoactive substance cyclopropylfentanyl has 
been suspended.
Twenty six countries provided a response to the EMA’s request 
regarding human and/or veterinary medicinal products (3). The 
EMA also provided information as relevant to the centralised 
procedure for authorising human and veterinary medicinal 
products.
(2) In alphabetical order: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Lithuania, 
Luxembourg, the Netherlands, Poland, Portugal, Slovenia, Spain, Sweden.
(3) Austria, Belgium, Croatia, Estonia, Finland, Germany, Greece, Iceland, Ireland, 
Italy, Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, 
and Sweden provided a response in relation to human and veterinary medicinal 
products. Cyprus, the Czech Republic, Denmark, and Hungary provided 
a response in relation to human medicinal products. France, Romania and the 
United Kingdom provided a response in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
cyclopropylfentanyl is used to manufacture a medicinal 
product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty six countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from the 28 Member 
States, Turkey, and Norway;
 ¡ reports previously submitted to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms, Progress Reports, and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not cyclopropylfentanyl has 
been assessed or is under assessment by the United 
Nations system; and,
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’).
Thus, the information included in sections 3.2.1 and 3.3 of 
the Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 
3.5, 3.6, 3.7, 3.8.1, 3.8.2, and 3.8.3 (in part). The information 
included in section 3.8.3 (in part) and section 4 was provided 
by the EMA.
(4) Austria, Belgium, Croatia, Estonia, Finland, Germany, Greece, Iceland, Ireland, 
Italy, Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain 
and Sweden provided a response in relation to human and veterinary medicinal 
products. Cyprus, the Czech Republic, Denmark and Hungary provided 
a response in relation to human medicinal products. France, Romania and the 
United Kingdom provided a response in relation to veterinary medicinal products.
I  3. Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
I  3.1 Chemical and physical description, including the names under which the new psychoactive substance is known (Article 5.2(a) of the Council Decision)
Chemical description and names
Cyclopropylfentanyl belongs to the 4-anilidopiperidine class of 
synthetic opioids. This class also includes fentanyl (5), which is 
internationally controlled, and a number of other fentanils.
A total of 15 fentanils are controlled under the United Nations 
Single Convention on Narcotic Drugs, 1961, as amended by 
the 1972 Protocol (6).
Cyclopropylfentanyl differs from fentanyl by 
replacement of the propionamide group of fentanyl with 
a cyclopropanecarboxamide group. Cyclopropylfentanyl 
is also structurally related to butyrfentanyl (7), which is 
internationally controlled, and differs from butyrfentanyl 
by replacement of the butyramide group with 
a cyclopropanecarboxamide group.
The synthesis of cyclopropylfentanyl has been described in 
the patent literature (Janssen, 1968).
The molecular structure, molecular formula, and molecular 
mass of cyclopropylfentanyl are provided in in Figure 1.
(5) N-Phenyl- N- [1- (2- phenylethyl) piperidinyl-4-yl]propanamide
(6) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, 
beta-hydroxyfentanyl, para-fluorofentanyl, thiofentanyl and acetylfentanyl are 
controlled under Schedule I and IV; alfentanil, fentanyl, sufentanil, remifentanil 
and butyrfentanyl are controlled under Schedule I.
(7) N-Phenyl-N-[1-(2-phenylethyl)piperidinyl-4-yl]butanamide 
5 / 16
JOINT REPORTS I Cyclopropylfentanyl
Commonly used names:  
cyclopropylfentanyl
Systematic (IUPAC) name:  
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
cyclopropanecarboxamide
Other chemical names:  
N-phenyl-N-[1-(2-phenylethyl)-4-piperidyl]
cyclopropanecarboxamide;
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-
cyclopropanecarboxamide;
N-(1-phenethylpiperidin-4-yl)-N-
phenylcyclopropanecarboxamide;
N-fenyl-N-[1-(2-fenyletyl)-4-piperidinyl]
cyklopropankarboxamid (Swedish);
N-(1-fenetylpiperidin-4-yl)-N-fenylcyklopropankarboxamid 
(Swedish)
Other names and code names:  
cyclopropyl fentanyl, cyclopropyl-fentanyl, cyclopropylfent
Street names 
‘cyclopropyl’ (Belgium),  
‘synthetic heroin’ (Belgium),  
‘4-me-MAF’ (Sweden),  
‘MAF’ (Poland)
Chemical Abstracts Service (CAS) registry numbers (8): 
1169-68-2 free base
(8) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
IUPAC International Chemical Identifier Key (InCHI Key) (9):  
OIQSKDSKROTEMN-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry number listed above. The searches returned no 
hits.
Physical description
Cyclopropylfentanyl contains one basic nitrogen atom in the 
piperidine ring which can readily form salts with organic or 
inorganic acids.
Limited solubility data available on cyclopropylfentanyl 
indicates that it is soluble in methanol; due to its similarity 
to fentanyl, the free base could be expected to be sparingly 
soluble in water; the hydrochloride and citrate salt could be 
expected to have greater aqueous solubility.
Cyclopropylfentanyl is expected to be lipophilic.
The measured melting point of cyclopropylfentanyl was 
reported as 119.5–120.4 °C (Janssen, 1968).
Cyclopropylfentanyl has been detected in powders and, to 
a lesser extent, in liquids and in tablets. A more detailed 
description of seizures and collected samples can be found in 
section 3.2.1 and section 3.2.2.
(9) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula, and molecular mass of cyclopropylfentanyl. Information on butyrfentanyl and fentanyl is 
provided for comparison.
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Detection and analysis
Methods documented in the literature for the detection of 
cyclopropylfentanyl include: gas chromatography–mass 
spectrometry (GC-MS) (Slovenian National Forensic 
Laboratory, 2017; SWGDRUG, 2017), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-ATR) 
(Slovenian National Forensic Laboratory, 2017; SWGDRUG, 
2017), gas chromatography–mass spectrometry–infrared 
spectroscopy (GC-(MS)-IR) condensed phase (Slovenian 
National Forensic Laboratory, 2017), and nuclear magnetic 
resonance (NMR) (SWGDRUG, 2017).
There is no information on the reaction of cyclopropylfentanyl 
to presumptive colour tests.
Cyclopropylfentanyl is not expected to give a positive 
response to immunoassays developed for morphine-type 
opioids. It is unknown if immunoassays for fentanyl will detect 
cyclopropylfentanyl. In addition, it is unknown whether such 
assays can distinguish between cyclopropylfentanyl and 
fentanyl (US DEA, 2017b). Identification of cyclopropylfentanyl 
requires confirmatory analysis (US DEA, 2017b).
I
  3.2 Information on the frequency, circumstances and/or 
quantities in which a new psychoactive substance is 
encountered, and information on the means and 
methods of manufacture of the new psychoactive 
substance (Article 5.2(b) of the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 20 Member States (Austria, 
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Lithuania, 
Luxembourg, the Netherlands, Poland, Portugal, Slovenia, 
Spain and Sweden), the Republic of Serbia, and Canada.
The level of production 
No information was received in relation to the production of 
cyclopropylfentanyl.
Sweden reported that there is no known production of 
cyclopropylfentanyl in the country. Vendors mix the substance 
in powder form with water and then they package the resulting 
solution into nasal spray bottles, ordered from China. This 
approach has been reported as characteristic for marketing 
fentanils in Sweden.
The level of distribution
Limited information was received in relation to the distribution 
(seizures) of cyclopropylfentanyl (10).
Sweden reported 26 seizures of cyclopropylfentanyl since the 
substance was introduced on to the market. They reported 
two ‘large seizures’ distributed via a postal-hub in Belgium.
Sweden reported that the substance is ordered from 
Swedish websites on the surface web and sent directly to 
the end user, or, in some cases, to relatives of the user. They 
also reported that there is no information to indicate that 
Swedish customers use cyclopropylfentanyl purchased from 
international websites.
As part of an ongoing investigation, it is estimated that 600 
people have purchased cyclopropylfentanyl from a specific 
webpage. However, it is not possible to confirm that all the 
purchases involved cyclopropylfentanyl. Cyclopropylfentanyl 
was reported to be available in Sweden as of 13 June 2017; 
a death associated with cyclopropylfentanyl was also reported 
on the same day.
The level of trafficking
Limited information was received in relation to the trafficking 
of cyclopropylfentanyl.
Sweden reported that the domestic postal service is used for 
the distribution of the substance which is ordered from China 
in powder form and then distributed to buyers via domestic 
postal services. There is no information to indicate that the 
substance is exported from Sweden.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member 
States, Turkey, and Norway. Of these, 5 Member States 
(Austria, Latvia, Poland, Sweden, and the United Kingdom) 
and Norway reported detections of cyclopropylfentanyl (11). 
(10) Canada reported two seizures of cyclopropylfentanyl. One seizure of 11 
grams of white powder originated in China and was concealed in bags of dog 
food/treats. The analysis confirmed the citrate salt of cyclopropylfentanyl 
(N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide). The 
second seizure was 268 grams of white powder, which originated in Hong Kong 
and, unlike the previous seizure, was not concealed. The analysis confirmed 
furanylfentanyl and cyclopropylfentanyl..
(11) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
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Images of seizures and collected samples reported to the 
EMCDDA are provided in Annex 1.
It is important to note that cyclopropylfentanyl may be under-
detected since the substance is not routinely screened for. 
Three Member States (Belgium, Slovenia, and Sweden) and 
Norway reported that cyclopropylfentanyl is part of routine 
screening in some (but not all) laboratories.
Seizures
In total, 57 seizure cases (12) were reported to the EMCDDA by 
4 Member States: Latvia (25 cases), Poland (2), Sweden (27), 
and the United Kingdom (3). Where known, the seizures took 
place between July and November 2017 and were made by 
police or customs agencies.
Cyclopropylfentanyl was detected in powders, and, 
to a lesser extent, in liquids and in tablets. Aside from 
cyclopropylfentanyl, no other substances were reported to 
have been detected in the seizures.
Powders
A total of 1.6 kg of powder containing cyclopropylfentanyl was 
seized in 26 cases that were reported by Latvia (18 cases), 
Poland (2), Sweden (4), and the United Kingdom (2). Where 
known, the powders were reported to be white or off-white in 
colour.
In 23 cases, the quantities seized were less than 5 g. However, 
in a case reported by Poland, two samples amounting to 
approximately 500 g each were seized. In this case, the 
substance was seized by Polish customs in parcels sent by 
post from China (via Belgium) to a private address in Poland 
in September 2017 (Annex 1); while in a case reported by 
Sweden, approximately 600 g was seized by customs (no 
additional details are available).
Liquids
A total of 240 mL of liquid containing cyclopropylfentanyl was 
seized in 27 cases that were reported by Latvia (7 cases), 
Sweden (19), and the United Kingdom (1).
The quantity seized ranged from 0.1 to 49 mL. In the cases 
reported by Latvia the liquids were recovered from syringes. 
In the case reported by the United Kingdom, a nasal spray 
containing 3.8 mL of a liquid containing cyclopropylfentanyl 
was seized.
(12) Many ‘seizures’ relate to individual cases, however, some data provided to the 
EMCDDA are aggregated at the country level. Data is drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU 
EWS Progress Reports and Final Reports) and from individual EMCDDA–Europol 
Reporting forms submitted to the EMCDDA on an ad hoc basis.
Tablets
A total of 87 tablets containing cyclopropylfentanyl were 
seized in 4 cases that were reported by Sweden.
Collected samples
A total of 4 collected samples containing cyclopropylfentanyl 
were reported by 3 Member States (Austria, Poland, and the 
United Kingdom) and Norway. All the samples were collected 
between June and October 2017.
In the two cases reported by Austria and the United Kingdom, 
the samples were purchased as a powder from the internet. In 
the case reported by the United Kingdom, acetylfentanyl was 
also detected in the powder.
In the case reported by Poland, the sample was collected from 
a user and was sold as ‘MAF’.
In the case reported by Norway, cyclopropylfentanyl was 
detected in a liquid in a nasal spray that was recovered 
from the scene of a death. Both cyclopropylfentanyl and 
acetylfentanyl were detected in the liquid as well as in 
a biological sample from the deceased (see section 3.4.1). It 
was reported that the user had used a ‘methoxyacetylfentanyl 
nasal spray’.
Biological samples
Serious adverse events with confirmed exposure to 
cyclopropylfentanyl from biological samples are discussed in 
section 3.4.2.
In addition to these, Sweden reported a suspected petty drug 
offence where cyclopropylfentanyl was analytically confirmed 
in a biological sample; the case occurred in September 2017.
I 
 3.3 Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the Council 
Decision)
No information concerning the involvement of organised 
crime in the manufacture and/or trafficking of the 
cyclopropylfentanyl was provided.
Sweden reported that the availability of cyclopropylfentanyl 
can be linked to two known vendors who sell substances on 
several domestic websites on the surface web. These vendors 
are both known to police and have been previously convicted 
of serious drug offences. It is thought that the vendors have 
contacts in China but it is unknown whether they use the 
same source for their products.
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Money laundering aspects
Limited information was received in relation to the money 
laundering in connection with the production and/or 
trafficking of cyclopropylfentanyl.
Sweden reported that the known vendors for fentanils in 
the Swedish domestic market sell the substances through 
established companies and that payment is through bank 
transfer, cash on delivery, bitcoin, or Swish (13). They 
reported that money laundering is considered an element in 
those cases. In addition, the sale of fentanils in Sweden is 
considered to be very profitable due to the relatively low cost 
of purchasing and distributing the substances compared to 
the financial gains.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale, and/or trafficking 
of cyclopropylfentanyl.
I 
 3.4 A first indication of the risks associated with the 
new psychoactive substance, including the health and 
social risks, and of the characteristics of users — 
Article 5.2(d) of the Council Decision
3.4.1 Health risks
Limited data suggests that cyclopropylfentanyl is a μ-opioid 
receptor agonist that shares some similarities with opioid 
analgesics such as morphine and fentanyl (Janssen and Van 
der Eycken, 1968; US DEA, 2017a; US DEA, 2017b).
The acute effects of these types of opioids include: euphoria, 
relaxation, analgesia, sedation, bradycardia, hypothermia, and 
respiratory depression. They also have an abuse liability and 
dependence potential (Herz, 1993; Kieffer, 1999, Pasternak 
and Pan, 2013; Pattinson, 2008; Romberg et al., 2003).
Similar to other opioid analgesics, the most serious acute 
health risk from using cyclopropylfentanyl is probably 
respiratory depression, which in overdose could lead to 
apnoea, respiratory arrest, and death (EMCDDA, 2017; 
Pattinson, 2008; White and Irvine, 1999). This risk may be 
greater due to: the difficulty in diluting the substance; a lack of 
experience with its effects and dosing; the use of other central 
nervous system depressants at the same time (such as other 
(13) Swish is a mobile app payment system which allows users to send money 
using a mobile phone connected to an online banking service. Swish is 
a payment system used between bank accounts in Sweden.
opioids, benzodiazepines, gabapentanoids, and alcohol); 
a lack of tolerance to opioids; and, using the substance alone 
(such as at home) which would make it more difficult for users 
to call for help in the case of poisoning.
Available information shows that fentanils are being sold to 
users in or as heroin or other illicit opioids, as well as used 
to make counterfeit (fake) medicines (such as fake opioid 
analgesics (‘pain killers’) and benzodiazepines). They may also 
be sold as or in other illicit drugs such as cocaine. As users will 
be unaware of this, it could increase the risk of life-threatening 
poisoning in opioid users and especially other user groups 
(such as cocaine users) who may have no existing tolerance to 
opioids
The antidote naloxone should reverse the respiratory 
depression and other features of acute poisoning caused 
by cyclopropylfentanyl (Kim and Nelson, 2015; Ujváry et 
al., 2017). Recent clinical and community experience in 
treating poisonings caused by fentanils suggests that larger 
than normal doses and repeated doses of naloxone may 
be required to manage the poisoning in some cases; longer 
periods of observation may also be required (EMCDDA, 2017).
While there is limited data for cyclopropylfentanyl, the chronic 
health risks might share some similarities to opioids such as 
heroin and other fentanils. This may include dependence.
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
No acute intoxications with confirmed exposure to 
cyclopropylfentanyl were reported to the EMCDDA (14).
Deaths reported to the EMCDDA
In total, 60 deaths with confirmed exposure to 
cyclopropylfentanyl were reported to the EMCDDA by Sweden 
(59 cases) and Norway (1 case). In addition, Latvia reported 
4 deaths with possible exposure to cyclopropylfentanyl (15); 
these 4 cases are not discussed further in this report.
The 60 deaths occurred between June and October 2017. 
Of these, 55 (92 %) were male and 5 (8 %) were female. 
The males were aged between 21 and 59 years (mean 33.2; 
median: 32); the females were aged between 25 and 32 
years (mean: 29; median: 30). A range of other substances 
were detected in the deaths, including other central nervous 
system depressants. Other opioids were detected in 16 cases; 
(14) Sweden reported 2 acute intoxications with suspected exposure to 
cyclopropylfentanyl. These cases are not discussed further in this report. 
(15) Latvia reported 4 deaths where syringes containing cyclopropylfentanyl 
where found next to the deceased. Analytical confirmation of exposure from 
biological samples is not available.
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in only one of these cases was another fentanil detected 
(acetylfentanyl). In all of the cases the decedents were 
either found dead or unconscious, predominantly in a home 
environment.
The cause of death was reported for 24 cases. In 23 cases, 
cyclopropylfentanyl was the cause of death or contributed to 
the death.
Serious adverse events identified in open source 
information
During 2017, more than 100 deaths associated with 
cyclopropylfentanyl were reported in the United States (US 
DEA, 2017b; Smith and Kinkaid, 2017) (16).
3.4.3 Characteristics of users
Similar to other new fentanils, cyclopropylfentanyl is sold and 
used as a ‘legal’ substitute for illicit opioids and prescription 
opioids medicines; this may include for self-medication, such 
as the alleviation of pain and/or opioid withdrawal. Users 
may include high-risk drug users as well as others (such as 
psychonauts) who may be experimenting with the substance.
3.4.4 Social risks
While there is limited data for cyclopropylfentanyl, the social 
risks might share some similarities with opioids such as heroin 
and other fentanils.
Of additional note is that in the past few years fentanils 
have been sold in Europe as ready-to-use nasal sprays and 
e-liquids for vaping. In general, these novel products could 
make it easier to use such substances (with similar effects to 
injecting) and make them more socially acceptable. Further 
research is required on this topic to better understand the 
risks.
Similar to other fentanils, accidental exposure to 
cyclopropylfentanyl may also pose a risk of poisoning. Those 
at risk may include the family and friends of users, law 
enforcement, emergency personnel, medical and forensic 
laboratory personnel, as well as those in custodial settings 
and postal services. Where required, these risks should be 
assessed and appropriate procedures, training, and protective 
measures should be implemented. This may include training in 
resuscitation and adequate provision of the antidote naloxone 
(IAB, 2017; White House National Security Council, 2017).
(16) In addition, an outbreak of poisonings that involved 26 non-fatal intoxications 
and 1 death was associated with counterfeit Percocet tablets that contained 
cyclopropylfentanyl and U-47,700 in Georgia during June 2017 (Edison et al., 
2017).
I 
 3.5 Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of the 
Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific, and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961, and the Convention on Psychotropic Substances, 1971.
On 22 October 2017, the World Health Organization informed 
the EMCDDA that cyclopropylfentanyl is currently not under 
assessment and has not been under assessment by the UN 
system.
I  3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official EMCDDA–Europol notification of 
cyclopropylfentanyl dates from 4 August 2017 from the 
Latvian national focal point. The Reporting Form details 
the seizure of cyclopropylfentanyl in 34.5 mg of white 
powder, seized by the police in Riga on 25 July 2017. The 
substance was analytically confirmed by the Forensic Service 
Department of the State Police by GC-MS, and a library match 
with the Cayman Spectral Library.
Cyclopropylfentanyl was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of 
the substance was created on the European Database 
on New Drugs (EDND). Since then, analytical details and 
other information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
Of note is that data from biological samples related 
to death cases reported to the EMCDDA shows that 
cyclopropylfentanyl has been on the market in Europe since at 
least June 2017.
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I 
 3.7 Information on whether or not the new 
psychoactive substance is already subject to control 
measures at national level in a Member State (Article 
5.2(g) of the Council Decision)
Eight Member States (Cyprus, Estonia, Finland, Ireland, Latvia, 
Lithuania, Sweden, and the United Kingdom) and Norway 
reported that cyclopropylfentanyl is controlled under drug 
control legislation.
Five Member States (Austria, Belgium, Germany, Hungary, and 
Poland) reported that cyclopropylfentanyl is controlled under 
specific new psychoactive substances control legislation.
Fifteen Member States (Bulgaria, Croatia, Czech Republic, 
Denmark, France, Greece, Italy, Luxembourg, Malta, the 
Netherlands, Portugal, Romania, Slovakia, Slovenia, and 
Spain) and Turkey reported that cyclopropylfentanyl is not 
subject to control measures at the national level.
I  3.8 Further information (Article 5.2(h) of the Council Decision)
3.8.1 The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, 
or Norway about the chemical precursors or manufacturing 
methods used to make the cyclopropylfentanyl which has 
been detected within Europe.
Two potential precursors of fentanyl and other fentanils 
— 4-anilino-N-phenethylpiperidine (ANPP) as well as 
N-phenethyl-4-piperidone (NPP, a pre-precursor) — 
have been recently scheduled under the United Nations 
Convention against Traffic in Narcotic Drugs and Psychotropic 
Substances, 1988 (17).
The synthesis of cyclopropylfentanyl has been described 
in the literature (Janssen, 1968) and the method included 
the use of ‘β-phenyl-ethyl’ and ‘N-(4-piperidyl)-N-phenyl-
cyclopropanecarboxamide’.
The manufacture of cyclopropylfentanyl can also rely on 
precursors and synthetic methods similar to those used 
for the manufacture of pharmaceutical fentanyl (Casy and 
Huckstep, 1988; Gupta et al., 2013; Zee and Wang, 1980). 
Therefore, the methods developed for the synthesis of 
(17) Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988.
fentanyl are applicable to the synthesis of cyclopropylfentanyl. 
Use of a different acylating agent in the final acylation step, 
such as cyclopropanecarbonyl chloride would produce 
cyclopropylfentanyl. A one-step method uses ANPP and 
cyclopropanecarbonyl chloride for the manufacture of the 
substance.
France reported that aniline, NPP, ANPP, and 
cyclopropanecarbonyl chloride could be used as potential 
precursors for the synthesis of cyclopropylfentanyl.
Most of the synthetic procedures that could be used for 
the synthesis of cyclopropylfentanyl are straightforward 
and use common laboratory equipment and precursors. 
Detailed methods are available on the internet (18). While 
only basic knowledge of synthetic chemistry is required, 
due to the potency of fentanils extreme caution is required 
when carrying out the final synthetic step as well as when 
purifying and handling the substance. Exposure of the skin 
and mucous membranes to fentanils as well as their inhalation 
pose a serious risk of accidental poisoning. In addition to 
exercising extreme caution, suitable personal protective 
equipment as well as sufficient stocks of naloxone as an 
antidote to poisoning following accidental exposure should 
be available when handling materials suspected to contain 
these substances (IAB, 2017; White House National Security 
Council, 2017).
In summary, the synthesis of cyclopropylfentanyl has been 
described in the literature. In addition, other routes developed 
for the manufacture of fentanyl may also be used. There is no 
information on the actual method(s) used for the production of 
cyclopropylfentanyl that has been detected in Europe to date.
3.8.2 The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of cyclopropylfentanyl. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
(18) The detailed description of the most common procedure, referred to as the 
‘Siegfried method’, is readily available on the internet (see, for example, http://
opioids.com/fentanyl/synthesis.html).
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3.8.3 Other use of the new psychoactive substance 
and the extent of such use, the risks associated with 
this use of the new psychoactive substance, including 
the health and social risks
No information was provided by the Member States, Turkey, or 
Norway that indicated that cyclopropylfentanyl had any other 
use apart from in analytical reference materials and scientific 
research.
From the available information, it does not appear that 
cyclopropylfentanyl is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
Ten countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Finland, Germany, Greece, Latvia, and the 
Netherlands) reported that cyclopropylfentanyl is not used 
to manufacture a medicinal product for human use. Thirteen 
countries (Cyprus, Estonia, Hungary, Iceland, Ireland, Italy, 
Norway, Poland, Portugal, Slovakia, Slovenia, Spain, and 
Sweden) reported that it was unknown if cyclopropylfentanyl 
is used to manufacture a medicinal product for human use.
In addition, the EMA reported that it is not known if 
cyclopropylfentanyl is used in the manufacture of medicinal 
products for human use and which are centrally authorised 
within the European Union.
Ten countries (Austria, Belgium, Croatia, Finland, France, 
Greece, Latvia, Poland, Romania, and the United Kingdom) 
provided information that cyclopropylfentanyl is not used to 
manufacture a medicinal product for veterinary use. Twelve 
countries (Estonia, Germany, Iceland, Ireland, Italy, the 
Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, and 
Sweden) reported that it was unknown if cyclopropylfentanyl 
is used to manufacture a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if 
cyclopropylfentanyl is used in the manufacture of medicinal 
products for veterinary use and which are centrally authorised 
within the European Union.
I  4. Information from the EMA (Article 5.3 of the Council Decision)
Twenty-three countries (Austria, Belgium, Croatia, Cyprus, 
Czech Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Latvia, the Netherlands, 
Norway, Poland, Portugal, Slovakia, Slovenia, Spain, and 
Sweden) reported that:
 ¡ cyclopropylfentanyl has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ cyclopropylfentanyl is not the subject of an application for 
a marketing authorisation as a medicinal product for human 
use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to cyclopropylfentanyl as a human 
medicine.
Twenty-two countries (Austria, Belgium, Croatia, Estonia, 
Finland, France, Germany, Greece, Iceland, Ireland, Italy, 
Latvia, the Netherlands, Norway, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom) 
reported that:
 ¡ cyclopropylfentanyl has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ cyclopropylfentanyl is not the subject of an application 
for a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to cyclopropylfentanyl as 
a veterinary medicine.
The EMA also reported that cyclopropylfentanyl:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
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I 5. Conclusion
Cyclopropylfentanyl belongs to a group of synthetic opioids 
known as the fentanils. It is closely related to fentanyl, which 
is controlled under the United Nations Single Convention on 
Narcotic Drugs, 1961. Data suggests that cyclopropylfentanyl 
may be an opioid narcotic analgesic in humans, and, as such, 
may have an abuse liability and dependence potential; overall, 
these effects may be broadly comparable to fentanyl. The 
most serious acute health risk posed by cyclopropylfentanyl 
is likely to be respiratory depression, which in overdose is 
life-threatening. The antidote naloxone should reverse this 
respiratory depression.
Cyclopropylfentanyl has been available in the European Union 
since at least June 2017. It has been detected in 5 Member 
States and Norway where it has been seized as a powder, 
liquids, and tablets. While the detected quantities are 
relatively small, they include 3 seizures of bulk quantities of 
powder weighing approximately between 500 and 600 g each. 
Overall, the quantities detected should be seen within the 
context of the high potency that is typical of the fentanils.
There are indications that the cyclopropylfentanyl currently 
available on the market is synthesised by chemical companies 
based in China. Cyclopropylfentanyl is sold online often under 
the guise of a ‘research chemical’. It is available, and, has been 
seized, in wholesale amounts and in consumer amounts.
A total of 60 deaths with confirmed exposure to 
cyclopropylfentanyl have been reported to the EMCDDA 
by Sweden (59 cases) and Norway (1). In at least 23 of 
the deaths, cyclopropylfentanyl was the cause of death or 
contributed to the death.
Cyclopropylfentanyl is sold and used as a substitute for illicit 
opioids and prescription opioids. Similar to other fentanils, 
serious concerns exist that the substance could be supplied 
surreptitiously to a range of drug users.
Cyclopropylfentanyl has not been assessed within the 
United Nations system nor is it currently under assessment. 
Cyclopropylfentanyl is not subject to control measures in 15 
Member States and Turkey.
Cyclopropylfentanyl does not appear to have any recognised 
human or veterinary medical use in the European Union.
We conclude that the health and social risks caused by the 
manufacture, trafficking, and use of cyclopropylfentanyl, 
as well as the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
cyclopropylfentanyl in order to ensure that new information is 
provided to the Member States, the EMA, and the Commission 
via the information exchange of the European Union Early 
Warning System.
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I  Annex 1  Images from seizures and collected samples provided to the EMCDDA
Country Image Description
Poland Seizure
Date: 5 September 2017
Seizing authority: Customs Services at the Polish Post
White powder; 1 package containing 495.4 grams and 1 package 
containing 499 grams.
The package was shipped from China and had transited through 
Belgium before it was seized in Poland.
United Kingdom Collected sample
Date: 22 August 2017
Collecting authority: TICTAC Communications Ltd.
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